Evidence map›Paper›PMID 22684020›Full record

ArticleFree radical biology & medicine2012

Regulatory role of KEAP1 and NRF2 in PPARγ expression and chemoresistance in human non-small-cell lung carcinoma cells.

Lijuan Zhan, Hao Zhang, Qiang Zhang, Courtney G Woods, Yanyan Chen, Peng Xue, Jian Dong, Erik J Tokar, Yuanyuan Xu, Yongyong Hou and 7 more

Erratum issuedAbstract read
In one paragraph

Article in Free radical biology & medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed.

  1. Article
  2. Article
  3. Frontiers in oncology · 2026
    Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Potential Applications of NRF2 Modulators in Cancer Therapy.Antioxidants (Basel, Switzerland) · 2020
    Review
  14. PPAR research · 2020
    Article
  15. Review
  16. Review
  17. TrxR1, Gsr, and oxidative stress determine hepatocellular carcinoma malignancy.Proceedings of the National Academy of Sciences of the United States of America · 2019
    Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors.

Lijuan ZhanInstitute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Hao Zhang
Qiang Zhang
Courtney G Woods
Yanyan Chen
Peng Xue
Jian Dong
Erik J Tokar
Yuanyuan Xu
Yongyong Hou
Jingqi Fu
Kathy Yarborough
Aiping Wang
Weidong Qu
Michael P Waalkes
Melvin E Andersen
Jingbo Pi

Funding

Stem Cell ToxicologyZIAES102925 · NIEHS · NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES · PI TOKAR, ERIK · 2010 to 2021
$25.3M
Paradoxical roles of Nrf2 activation in arsenic-induced beta-cell dysfunctionR01ES016005 · NIEHS · THE HAMNER INSTITUTES · PI PI, JINGBO · 2008 to 2012
$2.5M
NIEHS NIH HHS ES016005NIEHS NIH HHS R01 ES016005
6 · The paper itself

Abstract

The nuclear factor-E2-related factor 2 (NRF2) serves as a master regulator in cellular defense against oxidative stress and chemical detoxification. However, persistent activation of NRF2 resulting from mutations in NRF2 and/or downregulation of or mutations in its suppressor, Kelch-like ECH-associated protein 1 (KEAP1), is associated with tumorigenicity and chemoresistance of non-small-cell lung carcinomas (NSCLCs). Thus, inhibiting the NRF2-mediated adaptive antioxidant response is widely considered a promising strategy to prevent tumor growth and reverse chemoresistance in NSCLCs. Unexpectedly, stable knockdown of KEAP1 by lentiviral shRNA sensitized three independent NSCLC cell lines (A549, HTB-178, and HTB-182) to multiple chemotherapeutic agents, including arsenic trioxide (As(2)O(3)), etoposide, and doxorubicin, despite moderately increased NRF2 levels. In lung adenocarcinoma epithelial A549 cells, silencing of KEAP1 augmented the expression of peroxisome proliferator-activated receptor γ (PPARγ) and genes associated with cell differentiation, including E-cadherin and gelsolin. In addition, KEAP1-knockdown A549 cells displayed attenuated expression of the proto-oncogene cyclin D1 and markers for cancer stem cells (CSCs) and reduced nonadherent sphere formation. Moreover, deficiency of KEAP1 led to elevated induction of PPARγ in response to As(2)O(3). Pretreatment of A549 cells with PPARγ agonists activated PPARγ and augmented the cytotoxicity of As(2)O(3). A mathematical model was formulated to advance a hypothesis that differential regulation of PPARγ and detoxification enzymes by KEAP1 and NRF2 may underpin the observed landscape changes in chemosensitivity. Collectively, suppression of KEAP1 expression in human NSCLC cells resulted in sensitization to chemotherapeutic agents, which may be attributed to activation of PPARγ and subsequent alterations in cell differentiation and CSC abundance.

Indexed as

Drug Resistance, NeoplasmAntineoplastic AgentsAntioxidant Response ElementsArsenicalsArsenic TrioxideCarcinoma, Non-Small-Cell LungCell DifferentiationCell Line, TumorCell SurvivalDoxorubicinEtoposideGene Expression RegulationGene Knockdown TechniquesGlutamate-Cysteine LigaseHeme Oxygenase-1HumansAntineoplastic AgentsArsenicalsArsenic TrioxideDoxorubicinEtoposideGCLM protein, humanGlutamate-Cysteine LigaseHeme Oxygenase-1HMOX1 protein, humanIntracellular Signaling Peptides and ProteinsKEAP1 protein, humanKelch-Like ECH-Associated Protein 1MAS1 protein, humanNAD(P)H Dehydrogenase (Quinone)NFE2L2 protein, humanNF-E2-Related Factor 2NQO1 protein, humanOxidesPPAR gammaProto-Oncogene MasRosiglitazoneThiazolidinediones

Identifiers

PMID22684020
PMCPMC3418425

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.